Search

Your search keyword '"Geisbert, Thomas W."' showing total 1,084 results

Search Constraints

Start Over You searched for: Author "Geisbert, Thomas W." Remove constraint Author: "Geisbert, Thomas W."
1,084 results on '"Geisbert, Thomas W."'

Search Results

152. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses

154. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

155. Ultrasensitive point-of-care immunoassay for secreted glycoprotein detects Ebola infection earlier than PCR

156. Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization

158. Functional cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein

159. Framework for leadership and training of Biosafety Level 4 laboratory workers

160. Filovirus infection induces an anti-inflammatory state in Rousettus bats

161. Additional file 1 of Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase

162. Panmicrobial oligonucleotide array for diagnosis of infectious diseases

165. Immune protection of nonhuman primates against ebola virus with single low-dose adenovirus vectors encoding modified GPs

166. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment

167. MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fevers

168. Asymmetric and Non-Stoichiometric Recognition Results in Broad Protection Against Ebolaviruses by a Two-Antibody Cocktail

170. Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein

171. Establishment of an African green monkey model for COVID-19 and protection against re-infection

175. Evaluation in nonhuman primates of vaccines against Ebola virus. (Perspectives)

179. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

180. Alpha-1-antitrypsin and its variant-dependent role in COVID-19 pathogenesis

182. Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase

183. Author Reply to Peer Reviews of Marburg and Ebola virus infections elicit a complex, muted inflammatory state in bats

184. Neutralizing Antibodies against Crimean–Congo Hemorrhagic Fever Virus Derived from a Human Survivor

186. Establishment of an African green monkey model for COVID-19

187. Ebola

188. Structural and functional analysis of cooperativity in a potent human antibody cocktail against Ebola virus

189. Marburg and Ebola virus infections elicit a muted inflammatory state in bats

190. Prior vaccination with the rVSV-ZEBOV vaccine does not interfere with but improves the efficacy of postexposure antibody treatment in nonhuman primates exposed to Ebola virus

192. Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38

193. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization

194. Ebola and Marburg Virus Infection in Bats Induces a Systemic Response

195. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death

197. A Cross-Reactive Humanized Monoclonal Antibody Targeting Fusion Glycoprotein Function Protects Ferrets Against Lethal Nipah Virus and Hendra Virus Infection

199. Outbreaks of filovirus hemorrhagic fever: time to refocus on the patient

Catalog

Books, media, physical & digital resources